Starts-up
Angelita Rebollo, a researcher at Insem, is the co-founder of PEP-Therapy, a medical biotechnology company that develops targeted therapeutic peptides for oncology, with its first product currently in Phase Ib. This first product is a bifunctional peptide consisting of a penetration sequence combined with a cargo that blocks the interaction between two proteins involved in tumor transformation.
The company was founded in 2014 based on Angelita Rebollo’s patents and research conducted at Sorbonne University and the Institut Curie.
- Vincent Boudy and Nathalie Mignet are the co-founders of the startup Imisca. The company aims to develop in situ immunotherapy approaches for gastric cancer based on UTCBS’s sol-gel patents.